
Eisai owns 1 brand in our database. Browse the complete portfolio of Eisai subsidiaries and brands across various industries.
Company Type
public
Headquarters
Tokyo, Japan
Brand Portfolio
1 brands
Stock
Tokyo Stock Exchange: 4523
What does Eisai own?
Eisai owns a pharmaceutical portfolio including Leqembi, Aricept, Fycompa, Lenvima, and Halaven, plus associated patents and manufacturing. It co-develops Leqembi with Biogen but leads the program.
Is Eisai publicly traded?
Yes. Eisai trades on the Tokyo Stock Exchange under the ticker 4523, organized as a holding company since 2021.
Who founded Eisai?
Toyoji Naito founded Nihon Eisai in Tokyo in 1941. The Naito family remains influential, with grandson Haruo Naito serving as chief executive.
Where is Eisai headquartered?
Eisai is headquartered in Tokyo, Japan, with major operations in the US, Europe, China, and Asia.
What is Eisai's most important product?
Leqembi (lecanemab), the anti-amyloid Alzheimer's antibody co-developed with Biogen, is its main growth product. Aricept was historically its flagship.
Who owns Eisai?
Eisai is publicly owned through its Tokyo Stock Exchange listing, with the founding Naito family retaining influence through shareholding and leadership.
No competing brands found in the same categories. This could be because Eisaioperates in unique market segments or we're still building our competitor database.
Eisai maintains a diverse portfolio of 1 brands across multiple industries. This comprehensive brand portfolio demonstrates the company's market presence and strategic business units.
For consumers and researchers interested in corporate ownership structures, understanding which brands are owned by Eisaiprovides valuable insights into market dynamics, product relationships, and corporate strategy.